Goodwin Procter attorneys guided long-standing client, Inverness Medical Innovations, in a debt tender offer in which Inverness purchased all $150 million in aggregate principal amount of its 8.75% senior subordinated notes due 2012. Goodwin Procter originally represented Inverness in the placement of these notes in 2004. The debt tender was done in conjunction with Inverness’ $1.6 billion tender offer for Biosite Incorporated.
Both the debt tender offer and the Biosite tender offer were launched on May 29, 2007 and were completed on June 26, 2007. The debt tender offer, which resulted in 100% of the notes being purchased by Inverness, also included a consent solicitation which would have stripped any notes that remained outstanding of their covenants in order to permit Inverness to complete the Biosite acquisition.